Related Experiment Video
Updated: Jan 7, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
A Proposed Algorithm for the Management of Patients with Cardiogenic Shock Based on Contemporary Knowledge and Gaps
Aidonis Rammos1, Christos D Floros1, Ioannis Tzourtzos1
1Second Department of Cardiology, University Hospital of Ioannina, 45500 Ioannina, Greece.
Insights
Cardiogenic shock (CS) management requires improved evidence for intravenous therapies and mechanical circulatory support (MCS). A proposed algorithm highlights gaps, emphasizing early diagnosis and organized care to improve patient outcomes.
Area of Science:
- Cardiology
- Critical Care Medicine
Background:
- Cardiogenic shock (CS) presents a significant challenge with high mortality, even with advanced cardiac intensive care units (CICUs).
- Current therapeutic strategies rely on intravenous (i.v.) pressors and mechanical circulatory support (MCS) devices, guided by CS profile, etiology, and SCAI stage.
- Significant evidence gaps and controversies exist regarding optimal i.v. medications and MCS device utilization, compounded by variable availability and center experience.
Purpose of the Study:
- To propose an evidence-based algorithm for cardiogenic shock (CS) management.
- To identify and delineate critical gaps in the current therapeutic approaches for CS.
- To suggest strategies for bridging therapeutic disparities and improving CS outcomes.
Main Methods:
- This review synthesizes existing literature and clinical guidelines on cardiogenic shock (CS) management.
- An algorithm for CS management is developed, detailing therapeutic steps and decision points.
- Gaps in evidence and clinical practice at each stage of the proposed algorithm are identified.
Main Results:
- The proposed algorithm outlines a structured approach to CS management, incorporating i.v. therapies and mechanical circulatory support (MCS).
- Key evidence gaps were identified concerning the efficacy and selection of specific i.v. medications and MCS devices.
- Disparities in device availability and institutional experience were noted as significant challenges.
Conclusions:
- Addressing the identified evidence gaps through large-scale trials is crucial for optimizing CS treatment.
- Enhanced health system organization, including the establishment of specialized shock centers, is recommended.
- Early clinical suspicion, prompt diagnosis, and standardized management protocols are essential to improve outcomes in cardiogenic shock (CS).
Abstract:
Cardiogenic shock (CS) is a heterogeneous pathophysiological state with high mortality, despite the development of cardiac intensive care units (CICUs) and the advanced treatments applied. The cornerstones of therapy that have been proposed in many algorithms are intravenous (i.v.) pressors and devices for mechanical circulatory support (MCS), depending on the CS profile (left, right, or biventricular involvement), etiology (acute myocardial infarction, heart failure, or other) and SCAI stage (A to E, with MCS generally recommended for Stages C-E). There are many gaps in the evidence regarding i.v. medications and devices, with the existing data being controversial. Moreover, there are differences in the devices' availability and, as a result, a lack of experience in many centers. In this review article, an algorithm for the management of CS is proposed, and the gaps in every step are presented. Early clinical suspicion that leads to prompt diagnosis, health system organization, large-scale trials, and the configuration of national or regional shock centers could bridge the current therapeutic gaps and balance disparities in the management of CS in order to improve outcomes.
Related Concept Videos
Cardiopulmonary Resuscitation IV: Pharmacological Management
Heart Failure V: Medical Management
Acute Coronary Syndrome IV: Interprofessional Care
Blood Pressure Imbalances and Circulatory Shock
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Cardiomyopathy VI: Nursing Management
Cardiomyopathy V: Interprofessional Care

